Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Issue 2 (19th September 2011)

• Record Type: Journal Article
• Authors: Deuffic-Burban, Sylvie; Mathurin, Philippe; Pol, Stanislas; Larsen, Christine; Roudot-Thoraval, Françoise; Desenclos, Jean Claude; Dhumeaux, Daniel; Yazdanpanah, Yazdan
• Is Part Of: Gut. Volume 61:Issue 2(2012)
• Page Start: 290
• Page End: 296
• Publication Date: 2011-09-19
• Subjects: Chronic hepatitis C -- genotype 1 -- model-based analysis -- pegylated interferon and ribavirin -- protease inhibitor -- HCV, hepatitis C -- AIDS -- cost-effectiveness -- liver biopsy -- liver cirrhosis -- liver -- epidemiology -- hepatitis B -- hepatitis D -- HIV/AIDS, infectious disease -- HIV-related gastrointestinal disease; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2011-300586
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: The combination of pegylated interferon (PEG-IFN), ribavirin (RBV) and a protease inhibitor (PI) has been approved in summer 2011 for the treatment of genotype 1 (G1) hepatitis C virus (HCV)-infected patients, with a substantially improved efficacy. The aim of this study was to estimate the number of G1 patients to be treated in France in 2012 and associated costs. Methods: A published model of HCV and data on PEG-IFN sales were used to estimate patients needing treatment using three scenarios. (1) HCV screening rate unchanged versus 2010; proportion of treated F0–F1 patients unchanged, proportion of treated F2–F4 patients increased to the current proportion of treated F2–F4 G2/3 patients. (2) Scenario 1 but the proportion of treated F0–F1 patients increased to the current proportion of treated F0–F1 G2/3 patients. (3) Scenario 2 but a 5% increase in the HCV screening rate. To estimate cost, treatment duration was multiplied by drug unit cost. Probabilities corresponding to treatment duration were estimated based on liver fibrosis stage, treatment-naive or experienced status of the patient and virological response kinetics on treatment. Results: Compared with the 5100 G1 patients treated in 2010, the number of G1 patients receiving treatment in 2012 would be 15 000 in scenario 1, 18 300 in scenario 2 and 19 400 in scenario 3, among whom 2.5–3.7% may receive PEG-IFN/RBV and 96.3–97.5% PEG-IFN/RBV+PI. Costs associated with this regimen use ranged from 497 to 638 million Euros. Conclusion: These model-based estimates indicate that new anti-HCV treatments may result in a three- to fourfold increase in the number of G1 patients to be treated in France in 2012.